CMR Surgical Wins a Global Recognition Award 2026
More than 70% of the world’s surgical procedures are still performed as open surgery. Patients recover for weeks instead of days. Infection risks are higher. Furthermore, the robots capable of changing this have historically been available only to well-funded academic hospitals. The cost is too high. The footprint is too large. CMR Surgical built Versius to change that. It designed a modular, portable robotic system that moves between operating rooms, serves multiple specialties, and fits into hospitals that no previous robot could reach. Today, Versius has completed more than 40,000 procedures globally. Most importantly, it is the world’s second-most-utilized soft-tissue surgical robot. For that platform, CMR Surgical has earned a 2026 Global Recognition Award.
Technical Innovation and Architecture
The decision that defines Versius is architectural. Each robotic arm sits on its own compact wheeled bedside unit. As a result, arms can be configured freely around any patient and moved between operating rooms without permanent installation. Furthermore, the open surgeon console preserves full communication within the surgical team — the only major robot to do so. Additionally, reusable instruments with 13-use sterilizable cycles reduce per-procedure cost, making Versius economically viable where da Vinci is not.
Versius Plus — The Next Generation
Versius Plus received FDA 510(k) clearance in December 2025, enabling US commercialization in 2026. Furthermore, it integrates the Versius Connect surgeon app, live team dashboard, and real-time visualization. Additionally, in January 2026, CE and UKCA marks were granted for paediatric abdominal surgery — the first surgical robot approved for children under 18 in Europe. Consequently, CMR has opened robotic keyhole surgery to a patient population that no competitor currently serves.
Market Strategy and Leadership
CMR Surgical was founded in Cambridge in 2014 by five co-founders — including consultant surgeon Mark Slack, Cambridge device engineer Luke Hares, and Sagentia CEO Martin Frost. Consequently, Versius was designed from clinical reality rather than engineering assumptions. Current CEO Massimiliano Colella has led the company through four consecutive milestones in rapid succession: FDA De Novo (October 2024), $200M Series D extension (April 2025), Versius Plus 510(k) (December 2025), and paediatric CE mark (January 2026). Furthermore, Chris O’Hara leads US commercial operations as President & General Manager for the 2026 market entry.
Capital Structure and Clinical Validation
CMR has raised over $1.1 billion in total. The $600 million Series D led by SoftBank Vision Fund 2 valued the company at $3 billion — one of the largest European MedTech fundraises in history. Moreover, 40,000+ completed procedures are published in the Annals of Surgery and BJU International. Additionally, 70% of Versius hospitals use the system across two or more specialties — proving multi-departmental ROI. Consequently, CMR enters the US market as the world’s second-most widely used soft-tissue robot — proven, not experimental.
Industry Impact and Future Vision
The US market is the world’s largest surgical robotics market. However, da Vinci has dominated it for over two decades. Versius does not compete by matching da Vinci feature-for-feature. Instead, it targets hospitals that da Vinci’s capital costs have historically excluded. Furthermore, each new regulatory approval — cholecystectomy, paediatrics, and additional indications advancing systematically widens the addressable market.
The mission is concrete: not to beat da Vinci in large academic centers, but to reach district hospitals, community facilities, and emerging markets where keyhole surgery is not yet available. Moreover, 40,000 completed procedures outside the US prove this mission is executable. CMR Surgical earns the 2026 Global Recognition Award for building the surgical robot the world’s hospitals — and the world’s patients — have been waiting for.
Modular wheeled bedside arms: each arm on its own independent mobile unit — configures freely around any patient, moves between operating rooms, no fixed installation required
Open surgeon console: the only major surgical robot maintaining full team communication within the operating room — preserving clinical safety culture no competitor replicates
13-use sterilizable reusable instruments: per-procedure cost structure that materially undercuts single-use competitors — the economic architecture enabling hospital accessibility
Versius Connect: dedicated surgeon app logging all procedures; live clinical team dashboard tracking case volume, system efficiency, and usage patterns
Versius Plus (December 2025): FDA 510(k) cleared next-generation platform with enhanced visualization, AI-integrated analytics, and expanded procedure compatibility
Seven specialties supported: urology, general surgery, gynaecology, thoracic surgery, colorectal, hernia, and now paediatric abdominal — one system across a full hospital’s surgical portfolio
40,000+ surgical procedures completed globally as of December 2025 — the world’s second most-utilized soft tissue surgical robot, behind only da Vinci
70% of Versius hospitals deploy across two or more specialties — the most concrete proof of modular multi-departmental ROI at scale
FDA De Novo authorization (October 2024) + 510(k) clearance (December 2025): two FDA approvals in 14 months — fastest US regulatory progression of any surgical robot in its class
CE/UKCA mark for paediatric surgery (January 2026): first surgical robot approved for robotic abdominal surgery in children under 18 in Europe
Clinical evidence published in Annals of Surgery, International Journal of Surgery, and BJU International — the peer-reviewed publication record hospital procurement requires
$1.1B+ total raised at $3B valuation: $600M Series D (SoftBank Vision Fund 2, 2021) + $200M extension (SoftBank + LGT, April 2025)
US commercialization 2026: Versius Plus launch in the world’s largest surgical robotics market — entering with 40,000 completed procedures as clinical proof, not in experimental mode
Second most-utilized soft tissue surgical robot globally: market position achieved without US revenue — a foundation that makes the US launch an acceleration, not a debut
Paediatric surgery market: January 2026 CE mark opens a patient population no competitor currently serves with a robotic system
Modular vs. fixed-tower differentiation: Versius targets the hospitals da Vinci’s capital cost has historically excluded — a different market, not a head-to-head feature contest
Additional US indications pipeline: cholecystectomy is the first US indication; CMR is “diligently advancing additional indications” — systematically expanding the addressable US procedure base
Cambridge Innovation Capital portfolio company: participation across multiple rounds reflects the Cambridge ecosystem’s long-term commitment to CMR as a flagship deep-tech company
Moves between operating rooms: single Versius system serves multiple departments and floors without reinstallation — maximizing capital asset utilization across an entire hospital
Open console communication: surgeon remains visually and verbally present with the clinical team throughout procedures — surgical safety culture preserved at all times
Versius Connect app: surgeons log and review all procedures digitally; outcome data generates clinical improvement insights and evidence for hospital quality programs
Faster operating room setup: modular arm units set up independently and flexibly — reducing OR prep time versus single-tower fixed systems that require full repositioning
Compatible with existing OR infrastructure: no dedicated room or fixed installation required — integration into standard operating rooms without construction or modification
Clinical trials active in paediatrics at Southampton, Guy’s & St Thomas’, Manchester University NHS, and Liverpool University Hospitals — generating the UK clinical evidence base
Mission: “transforming surgery for good” — designed for permanence and for the billions of patients globally who currently cannot access minimally invasive keyhole surgery
Paediatric approval: January 2026 CE mark gives children access to robotic minimally invasive surgery — reducing recovery time, infection risk, and scarring in the most vulnerable surgical patients
Reusable instrument architecture: 13-use sterilizable cycles reduce medical device waste versus single-use competitors — a sustainability advantage at scale across 40,000+ procedures
Accessibility by design: smaller footprint, movable arms, lower per-procedure cost — all deliberate choices to reach district hospitals and emerging markets beyond premium academic centers
Open console safety culture: team communication preservation during surgery is both a clinical safety and an ethical design commitment — surgeons and teams function better together
NHS clinical trial partnerships: Southampton, Guy’s & St Thomas’, Manchester, and Liverpool University Hospitals — Versius is embedded in the UK’s national healthcare evidence-generation infrastructure
